Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 11, 2013, Pages 1756-1761

  Kim, Hwi Young ^a   Park, Joong Won ^a   Joo, Jungnam ^a   Kim, Hyoseok ^a   Woo, Sang Myung ^a   Lee, Woo Jin ^a   Kim, Chang Min ^a  

^a National Cancer Center   (South Korea)

Author keywords

Child Pugh classification; Hepatocellular carcinoma; Sorafenib; Survival

Indexed keywords

SORAFENIB;

ADULT; ADVANCED CANCER; ANOREXIA; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILD PUGH SCORE; DIARRHEA; DISEASE SEVERITY; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

CHILD-PUGH CLASSIFICATION; HEPATOCELLULAR CARCINOMA; SORAFENIB; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASCITES; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84897670620     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12310     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E etal. Cancer statistics, 2008. CA Cancer J. Clin. 2008; 58: 71-96.
2. Benson AB, 3rd, Abrams TA, Ben-Josef E etal. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. Journal of the National Comprehensive Cancer Network: JNCCN. 2009; 7: 350-391.
3. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378-390.
4. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
5. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
6. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012; 56: 908-943.
7. Di Maio M, Daniele B, Perrone F. Targeted therapies: role of sorafenib in HCC patients with compromised liver function. Nat. Rev. Clin. Oncol. 2009; 6: 505-506.
8. Park JW. [Practice guideline for diagnosis and treatment of hepatocellular carcinoma.] Korean J. Hepatol. 2004; 10: 88-98.
9. Korean Liver Cancer Study Group and National Cancer Center (Korea). Practice guidelines for management of hepatocellular carcinoma 2009. Korean J. Hepatol. 2009; 15: 391-423.
10. Kim HY, Park JW, Nam BH etal. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments. J. Gastroenterol. Hepatol. 2011; 26: 1612-1618.
11. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin. Liver Dis. 2010; 30: 61-74.
12. Therasse P, Arbuck SG, Eisenhauer EA etal. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 2000; 92: 205-216.
13. Abou-Alfa GK, Schwartz L, Ricci S etal. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2006; 24: 4293-4300.
14. Lencioni R, Kudo M, Ye SL etal. First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study. Int. J. Clin. Pract. 2012; 66: 675-683.
15. Pinter M, Sieghart W, Graziadei I etal. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009; 14: 70-76.
16. Worns MA, Weinmann A, Pfingst K etal. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J. Clin. Gastroenterol. 2009; 43: 489-495.
17. Abou-Alfa GK, Amadori D, Santoro A etal. Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis. Gastrointest. Cancer Res. 2011; 4: 40-44.
18. Baek KK, Kim JH, Uhm JE etal. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. Oncology 2011; 80: 167-174.
19. Kim JE, Ryoo BY, Ryu MH etal. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother. Pharmacol. 2011; 68: 1285-1290.
20. Chiu J, Tang YF, Yao TJ etal. The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits. Cancer 2012; 118: 5293-5301.
21. Shim JH, Park JW, Choi JI, Park BJ, Kim CM. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. J. Cancer Res. Clin. Oncol. 2009; 135: 617-625.
22. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol. 2006; 44: 217-231.
23. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N. Engl. J. Med. 2004; 350: 1646-1654.
24. Planas R, Montoliu S, Balleste B etal. Natural history of patients hospitalized for management of cirrhotic ascites. Clin. Gastroenterol. Hepatol. 2006; 4: 1385-1394.